Ir para o conteúdo principal

TransMedics Group (NASDAQ: TMDX) — Perfil da empresa, notícias e dados financeiros

Logo de TransMedics Group
TMDX TransMedics Group
TransMedics Group primary media
Perfil da empresa

TransMedics Group

TransMedics Group (NASDAQ:TMDX) is at the forefront of pioneering medical technology dedicated to improving the process and outcomes of organ transplant therapies. Specializing in portable perfusion systems, TransMedics brings new life to organs outside the body, enabling longer preservation and assessment times which are critical for successful transplants. Their innovative Organ Care System (OCS) has revolutionized the way organs are maintained from donor to recipient, focusing on lungs, heart, and liver transplants. The company's mission is to increase the availability and utilization of organs for transplantation, thereby transforming the field and offering hope to a greater number of patients on transplant waiting lists worldwide. Through ongoing research and development, TransMedics aims to continue expanding its product portfolio and improving transplant success rates, reflecting their commitment to saving lives and enhancing the quality of healthcare in organ transplantation.

Resumo

Public USParticipação acionária
1998Ano de fundação
350Funcionários
Andover, United StatesSede
Carregando mapa...
Presença global

Operações

Todos os locais
United States

Produtos e/ou serviços de TransMedics Group

  • Organ Care System (OCS) Heart, a platform designed to preserve and assess donor hearts for transplantation.
  • OCS Lung, a system for maintaining and evaluating donor lungs outside the body.
  • OCS Liver, aimed at optimizing the preservation, viability, and assessment of donor livers.
  • Portable Organ Care System (OCS) Kidney, enhancing kidney transplant success rates through better preservation techniques.
  • TransMedics Organ Care System (OCS) Connect, a comprehensive data platform for real-time monitoring and support of organ transportation.
  • Clinical Trial Services, providing expertise in the execution and management of trials for organ preservation and transplantation technologies.

equipe executiva do TransMedics Group

  • Waleed H. HassaneinFounder, President, CEO & Director
  • Nicholas CorcoranSenior Vice President of Supply Chain & Operations
  • Tamer I. KhayalSenior Vice President of International
  • Fernando AraujoChief Financial Officer & Treasurer
  • Matthew ForsythSenior VP, General Counsel & Corporate Secretary
  • Miriam C. ProvostVice President of Global Regulatory Affairs

Principais indicadores financeiros

Resultados divulgados pela TransMedics Group, em USD.

Cap. de mercado
2,3 bi
Receita (TTM)
668,5 mi
P/L
18.1
LPA (diluído, TTM)
3.7
Dividend yield
—
Margem de lucro
22.7%
Receita e lucro anuais da TransMedics Group
Fim do ano fiscalReceitaResultado operacionalLucro líquido
605,5 mi108,6 mi190,3 mi
441,5 mi37,5 mi35,5 mi
241,6 mi-28,7 mi-25 mi
93,5 mi-31,4 mi-36,2 mi